



IAS 2019



10TH IAS CONFERENCE ON HIV SCIENCE

Mexico City, Mexico  21-24 July 2019



IAS 2019

10TH IAS CONFERENCE ON HIV SCIENCE

Mexico City, Mexico 21-24 July 2019

occurrences of neural tube defects among 382 women on Dolutegravir at pregnancy conception in Brazil

IAS 2019 Co-chairs' choice, 22 July 2019
MOAX0104LB

G. Pereira, A. Kim, E. Jalil, F. Fernandes Fonseca, B. Shepherd, V. Veloso, R. Rick, R. Ribeiro, A. Beber, Jayathilake, R. Girade, R. Lima, F. Maruri, A. Caruso, C. McGowan, A. Benzaken, J. Castilho, B. Grinsztejn

The National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil



FIOCRUZ
Fundação Oswaldo Cruz



CCASAnet



National Institute of
Allergy and
Infectious Diseases



MINISTÉRIO DA
SAÚDE



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Conflict of Interest Disclosure

I have no conflict of interest.



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

How was it possible?

Universal HIV care & ART free of charge (1996)

Computerized ART distribution system
(CLOM)

Every person on ART

Rules based on national guidelines

DTG for 1st line (2017)

Use in pregnancy systematically restricted

As of May 2018 > 22,624 women between

15 and 49 years were on DTG in Brazil

DTG signal led to a national investigation

by May 2018

39,865
PLHIV switch to DTG as 3rd line



570,176
people on ART (2017)

7
PLHIV initiated

112,887
on DTG

Dolutegravir use in



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Aim

to estimate the risk of NTD in infants born to women receiving DTG and non-DTG ART regimens at time of conception in Brazil

Primary outcomes of interest:

- All NTD
 - Stillbirths
 - Abortions*
- Composite outcome**
for multivariable analyses

*Spontaneous abortions are illegal in Brazil. All abortions presumed to be spontaneous.



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Methodology

Prospective cohort of **every women** identified in SICLOM
possible exposure to DTG or RAL during pregnancy
(2015-2018)


Exposed group: pool of women with **exposure to EFV**
during pregnancy (2015-2018)

EFV 3: DTG 1


Systematic data collection by trained public health
professionals:

Chart review of all health services


Maternal demographic, behavioral, HIV history, comorbidities,
obstetrical history, prenatal care, and birth outcomes



HIV clinic



Antenatal clinic



Maternity



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Methodology

Exposure: **periconception window** (16-week period)

+/- 8 weeks of estimated date of conception (EDC)

- (1) 1st or 2nd trimester ultrasound (preferred method),
- (2) last recorded menstrual period (LMP), and
- (3) gestational age at delivery or 3rd trimester ultrasound

Statistical approach:

Calculation of NTD incidence with Wilson 95% CI among women with and without DTG exposure

Matched propensity score weighted logistic regression for composite pregnancy outcome for

- Any DTG vs. EFV only
- Sensitivity analyses: Only DTG vs. Only EFV / Only DTG or RAL vs. Only EFV

Used multiple imputation for missing data



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Results


Inclusion Criteria

Women with possible DTG or RAL exposure during pregnancy;
Indication of pregnancy in SICLOM,
Women of childbearing age on DTG whom were switched to an approved ART regimen for pregnancy,
Women who received IV AZT one time.

Exclusion Criteria

Unconfirmed pregnancy
Periconception ART exposure
Exposure including medications other than DTG, EFV
Missing/unknown periconception ART or birth outcomes

Women with possible prenatal exposure



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Report Creation



Total pool of **presumed pregnancies**
(SICLOM: 1/2015-5/2018)
N=3390 women

Pregnancies with **complete investigation**
N=2507



Women with **exclusion criteria**
N=1039

2 NTD cases:

- Started RAL at week 9 of pregnancy: myelomeningocele and spina bifida
- Started EFV at week 10 of pregnancy: myelomeningocele

NEITHER WOMEN HAD ANY EXPOSURE TO DTG BEFORE OR DURING PREGNANCY!




Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Periconception final cohort

N=1468

(women with EFV, DTG, or RAL within 8 weeks of EDC)

**Any DTG
N= 382**



**Any RAL
N= 125**

**Any EFV
N= 111**



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Table 1. Maternal characteristics at EDC

	No DTG (N=1086)	Any DTG (N=382)
Age, median (IQR)	28.4 (23.2-33.3)	26.6 (21.9-31.9)
Time to HIV diagnosis	2014 (2011-2016)	2017 (2014-2017)
Time since HIV diagnosis	2.9 (1.4-6.1)	0.7 (0.3-2.7)
CD4 count (cells/ μ L)	605 (420-838)	530 (375-751)
CD4 A below limit of detection	483 (74)	139 (58)
Adverse pregnancy outcome	376 (35)	128 (34)
Contraceptive use	209 (19)	78 (20)
Oral use	177 (16)	77 (20)
Injection use	117 (11)	54 (14)



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Table 2. Prenatal characteristics

	No DTG (N=1086)	Any DTG (N=382)
Number of ART regimens, median (IQR)	1.0 (1.0-2.0)	2.0 (2.0-2.0)
Iron and folic acid supplementation, n (%)		
Any before pregnancy	18 (2)	11 (3)
Any during pregnancy	488 (45)	183 (48)
Both before and during pregnancy	26 (2)	10 (3)
Unknown	554 (51)	178 (47)
Less than 6 total prenatal visits	410 (38)	175 (46)
Yes	63 (6)	40 (11)
No	3 (0)	0 (0)
Chronic hypertension	35 (3)	25 (7)



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Outcomes

the total 1452 birth outcomes, **there were no NTD observed**

DTG-exposed women incidence = 0 [95% CI: 0, 0.0099]

DTG-unexposed women incidence = 0 [95% CI: 0, 0.003]

	No DTG (N=1068)	Any DTG (N=384)	P value
NTD	0 (0)	0 (0)	-
Live birth	1025 (96.0)	359 (93.5)	<0.01
Stillbirth	15 (1.4)	2 (0.5)	
Abortion	28 (2.6)	23 (6.0)	



Composite Outcome Regression Models


Weighted PS Models

EDC Covariates

EDC + Prenatal Covariates

Covariates: age, education, race, years since ART initiation, time since HIV diagnosis, CD4 cell count, viral RNA below limit of detection, history of epilepsy or antiepileptic drug use, tobacco, alcohol, injection drug use, number of previous pregnancies, prior adverse pregnancy outcomes, folic acid use, BMI

Covariates: number of antenatal visits, syphilis, diabetes, hypertension, average weight gain per week



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Limitations

Retrospective study

Missing data

Preconception ART exposure

While we observed no NTD events in our analysis cohort, it is possible that our study remained underpowered to detect a difference in exposure groups



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Conclusions

occurrences of NTD in this national cohort study.

olic acid supplementation in Brazil: Enriched flour and high

valence of prenatal supplementation in this study

armacovigilance is a priority for the Ministry of Health in Brazil

results of this study do not conclusively indicate increased or

creased risk of stillbirth and/or abortion associated with

ericonception DTG exposure.



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Acknowledgements

Coordinators:

South Region

Andrea Maciel de Oliveira Rossoni
Deisy Rodrigues Felicio de Souza
Glaucia Harumi Maruo Kanabushi
Maysa Mabel Fauth
Hellen Corrêa Teixeira Cordeiro
Jacqueline A. Pruner Polidoro
Juliana Rita Pinheiro
Andreza Madeira Macário
Carla Félix dos Santos
Daniela Dal Forno Kinalski
Emanuele Lopes Ambrós
Lisiane Bernhard Hinterhol
Silvia Marielli da Costa Madeira
Solange de F. Mohd Suleiman Shama
Virginia de Menezes Portes
Simone Gonçalves Senna

Northeast Region

Dayana Tenório da Silva Mendonça
Luciana Maria Rodrigues de Oliveira
Fabrina Lopes Ferreira
Heloise Maria Morais de Andrade
Joselina Soeiro de Jesus
Maria Vilani de Matos Sena
Telma Alves Matins
Joseneide Teixeira Câmara
Joanna Angelica Araujo Ramalho
Andreza da Silva Sontos
Lavínia Sobral Barreto Nunes
Márcia Maria Cavalcanti Marcondes
Mônica da Silva Pinto Cronemberger
Simone Alli Fernandes Farias
Stella Rosa de Sousa Leal
Bruna Emanuelle Feitosa Vasconcelos

Midwest Region

Luciana Melo de Moura
Adriana Queiroz de Campos
Miriam Estela de Souza Freire
Aneth da Silva Benites Lino
Thiago Theodoro Martins Prata
Izôlda Maria Passos Lucena
Maria Joelma Pereira da Silva

North Region

Adriana Raquel Nunes de Souza
Ana Celia da Silva Moura
Chriscie Klen de Melo Rodrigues
Jeanne Silva da Costa
Valdirene Oliveira Cruz
Andréa Carolina Chagas de Miranda
Carla Gisele Ribeiro Garcia
José Arimateia Rodrigues Reis
Rutineide Queiroz Pantoja
Caroline Biserra Costa da Luz

Southeast Region

Benisia Maria Barbosa Cordeiro
Carla Joelma Villares Guimarães
Danielle Portela Ferreira
Janete Duarte Teixeira Duarte
José Alfredo de Sousa Moreira
Joseane Pessanha Ferreira
Luciana Castaneda Ribeiro
Lucrecia Helena Loureiro
Wilsa Mary Sousa dos Santos
Akemi Fumonke
Ana Cristina Barbosa
Carolina Simone Souza Adania
Cláudia Camargo Lorite
Cristina Magnabosco
Dirce Maria de Moura Prado
Luiz Roberto Lourenço
Maria Cristina Longo
Maria Emilia Braitte
Michelle Abou Dehn
Norma Noguchi
Tatiane Comerio
Cristiane Campos Monteiro
Maria Ângela dos Santos Pereira
Renata Siqueira Julio
Rita Sibeles de Souza Esteves

Coordinators: Gerson Winkler, Luciana Garritano, Sandra Gomes, Silvia Fruet

National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil: Gerson Pereira, Ahra Kim, Emilia Jalil, Fernanda
Andres Fonseca, Bryan Shepherd, Valdilea Veloso, Fernanda Rick, Rachel Ribeiro, Andrea Beber, Karu Jayatilake, Renato Girao
Lima, Fernanda Maruri, Catherine McGowan, Adele Benzaken, Jessica Castilho, Beatriz Grinsztejn



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**



IAS 2019

10TH IAS CONFERENCE ON HIV SCIENCE
Mexico City, Mexico 21-24 July 2019

Thank you!
Gracias!
Obrigada!



MINISTÉRIO DA
SAÚDE



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

clusion Criteria

The identification of potential DTG exposures during pregnancy included:

- Indication of pregnancy in SICLOM,
- Women of childbearing age on DTG that underwent ART change to an ART regimen recommended during pregnancy,
- Women who received a single dose of IV AZT.

Selection of unexposed group included women with possible exposure to EFZ during pregnancy from 2015 to 2018, on a 3:1 ratio.

- Unexposed women were balanced by geographic location with women possible exposed to DTG/ RAL



Exclusion Criteria

245 women who were not pregnant on chart review
52 women with unknown or missing birth outcomes

- Included 5 women with DTG exposure

713 were not on ART of interest during EDC window (either started after the window, were on other ART, or stopped before window)
29 had missing ART data from window EDC



Estimated Date of Conception

For each woman confirmed to have a pregnancy, we calculated the estimated date of conception by: 1st or 2nd trimester USG (preferred method), LMP, or EGA at delivery

N=146

1108 (76)

255 (17)

105 (7)

USG: subtracting the estimated gestational age reported from the first prenatal ultrasound occurring in the first or second trimester (preferred method), or

LMP: as the first day of the woman's last recorded menstrual period (if no ultrasound was obtained in the first or second trimester), or

EGA at delivery: by subtracting an estimated gestational age obtained from a third trimester ultrasound or at the time of delivery if no other data were available.



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**

Next Steps

evaluation of other adverse pregnancy outcomes using this cohort

evaluation of birth outcomes and DTG exposure later in pregnancy

case-control study based on national surveillance data to complete the investigation regarding neural tube defects, abortions and stillbirths among children perinatally exposed to HIV



Share your thoughts using **#IAS2019**
Find this presentation on **www.ias2019.org**